VIREAD® 300mg Tablet is a potent antiretroviral medication manufactured by Gilead Sciences, containing Tenofovir Disoproxil Fumarate (TDF) 300 mg per tablet. Specifically designed for managing HIV-1 infection and chronic hepatitis B virus (HBV) infection, this medication acts as a nucleotide reverse transcriptase inhibitor (NtRTI) which works by blocking the reverse transcriptase enzyme essential for viral replication. VIREAD® 300mg lowers the HIV viral load effectively while improving immune function and significantly reducing liver-related complications associated with chronic HBV. It is ideal for once-daily oral administration, offering convenience and adherence benefits for patients. Usage is recommended as part of combination antiretroviral therapy for HIV and as monotherapy or in combination for chronic HBV treatment. Dose adjustments are necessary for patients with renal impairment, and long-term therapy necessitates regular monitoring of bone density and kidney function. This medication is supplied in bottles of 30 film-coated tablets and must be stored properly, below 30°C, away from moisture and children, ensuring stability and efficacy.
Key Features
| Features | Description |
|---|---|
| Active Ingredient | Tenofovir Disoproxil Fumarate (TDF) 300 mg per tablet |
| Therapeutic Category | Antiviral / Antiretroviral |
| Indications | Treatment of HIV-1 infection (in combination therapy) and Chronic Hepatitis B infection |
| Mechanism of Action | Nucleotide reverse transcriptase inhibitor (NtRTI) blocking viral DNA replication |
| Dosage | 1 tablet (300 mg) once daily, with or without food |
| Packaging | Bottles containing 30 film-coated tablets |
| Storage Conditions | Store below 30°C, protect from moisture, keep tightly closed |
| Key Benefits | Suppresses HIV viral load, reduces liver inflammation and viral activity in HBV |
| Monitoring | Regular monitoring of kidney function and bone density recommended during long-term use |
| Attributes | Description |
|---|---|
| Manufacturer | Gilead Sciences |
| Composition per Tablet | Tenofovir Disoproxil Fumarate (TDF) 300 mg |
| Form | Film-coated tablet |
| Administration Route | Oral |
| Patient Group | Adults and adolescents with HIV-1 or chronic HBV infection |
| Storage Temperature | Below 30°C |
| Pack Size | 30 tablets per bottle |
| Renal Impairment Dose Adjustment | Required |
| Therapy Type | Combination therapy for HIV; monotherapy/combination for HBV |
| Safety Note | Use under medical supervision required |
| Shelf Life | As indicated on packaging (not specified) |
*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.
Yes, VIREAD 300mg can be used as monotherapy for chronic Hepatitis B infection in adults and adolescents; however, HIV co-infection must be ruled out before initiation.
Dose adjustment of VIREAD 300mg tablets is required in patients with impaired renal function. It is important to monitor kidney function regularly and consult a physician for appropriate dosage modifications.
Yes, VIREAD 300mg tablets can be administered with or without food without affecting its efficacy.
Long-term therapy with VIREAD 300mg may reduce bone mineral density; therefore, regular monitoring is advised during prolonged treatment.
No, VIREAD does not cure HIV or HBV infections but controls viral replication and improves clinical outcomes when used as part of combination therapy.
VIREAD 300mg is supplied in bottles containing 30 film-coated tablets.
Country Of Origin: India
Product Name: VIREAD® 300mg Tablet
Manufacturer: Gilead Sciences
Composition (per tablet):
• Tenofovir Disoproxil Fumarate (TDF) 300 mg
Therapeutic Category: Antiviral / Antiretroviral
Product Description:
VIREAD® 300mg is an antiretroviral medicine containing Tenofovir Disoproxil Fumarate (TDF), a nucleotide reverse transcriptase inhibitor (NtRTI). It is used in the treatment of HIV-1 infection and chronic hepatitis B virus (HBV) infection.
It helps lower viral load, improves immune function, and reduces liver-related complications in HBV patients. VIREAD is often used as part of combination therapy in HIV treatment.
Indications:
• HIV-1 infection (in combination with other antiretroviral agents)
• Chronic Hepatitis B infection in adults and adolescents
Mechanism of Action:
• Tenofovir inhibits the activity of reverse transcriptase, blocking viral DNA replication.
• This prevents multiplication of HIV and HBV in the body.
Dosage & Administration:
• Usual adult dose: 1 tablet (300mg) once daily, with or without food.
• Dose adjustment required in patients with renal impairment.
Key Benefits:
• Effective in suppressing HIV viral load.
• Reduces liver inflammation and viral activity in HBV.
• Once-daily convenient oral therapy.
Packaging:
• Bottles of 30 film-coated tablets.
Storage:
• Store below 30°C, tightly closed.
• Protect from moisture.
• Keep out of reach of children.
Important Notes:
• For use under medical supervision only.
• Not a cure for HIV/AIDS or HBV, but controls viral replication.
• Long-term therapy may affect bone density and kidney function—regular monitoring is advised.
ONCOLOGY EXPORTERS FROM INDIA
Melizza Lifescience
Inclusive of all taxes
You Save: 0
Rajkot , India
Manufacturer, Professional Services, Distributor, Exporter, Importer, Wholesaler, Startup
GST- 24gqfpm5460r1z4
